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Objectives RECORDAF is the first worldwide, prospective, observational survey of management of atrial fibrillation (AF) in
unselected, community-based patients.
Background Primary outcomes were therapeutic success and clinical outcomes associated with rhythm-control and rate-
control strategies.
Methods Patients with recent-onset AF were included (n  5,604). Treatment strategy (rhythm control or rate control) was
noted at baseline. Follow-up was 12 months. Therapeutic success required that strategy was unchanged without
clinical events. Further maintenance of sinus rhythm was required in the rhythm-control group, and heart rate
80 beats/min in the rate-control group.
Results Data from 5,171 patients were assessable. Therapeutic success was 54% overall (rhythm control 60% vs. rate
control 47%), a result driven by control of AF: rhythm control, 81% vs. rate control, 74%. After adjustment for
propensity score quintiles, the rhythm-control strategy was significantly related to superior therapeutic success
(odds ratio: 1.34, 95% confidence interval: 1.15 to 1.55; p  0.0002). Clinical events occurred in 18% of
patients. The arrhythmia management strategy was not predictive of clinical events. The type (persistent), pres-
ence at baseline visit, and duration (3 months) of AF, together with age older than 75 years and the presence
of heart failure, predicted progression to permanent AF. The choice of rhythm control reduced the likelihood of
AF progression (odds ratio: 0.20, 95% confidence interval: 0.17 to 0.25; p  0.0001).
Conclusions Clinical outcomes in AF patients were driven mainly by hospitalizations for arrhythmia/proarrhythmia and other cardiovas-
cular causes, but not by the choice of rate or rhythm strategy. Rhythm-control patients progressed less rapidly to permanent
AF. (J Am Coll Cardiol 2011;58:493–501) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.034In addition to appropriate antithrombotic treatment,
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the ventricular rate at a physio-
logical level while allowing the
atria to continue to fibrillate.
However, contrary to expecta-
tion, accumulated trial data indi-
cated that for the patient popu-
lations and specific therapies
evaluated, a rhythm-control
strategy was not superior to a
rate-control strategy with regard
to various major cardiovascular
endpoints (1–3).
Because enrollment is limited to patients who can be
randomized to either study arm and physicians must con-
done and support the allocated treatment for the duration of
the study, clinical trials do not always reflect usual clinical
practice. In addition, trials exploring the value of a treat-
ment strategy are critically dependent for their interpreta-
tion on the ability of the strategy to achieve its intermediate
goal, in this instance, maintenance of sinus rhythm or
persistence of adequate rate control. Some have criticized
the rate-versus-rhythm trials for such failures (4).
Although not protected by randomization, registry data
may provide complementary information to resolve further
the choice of treatment strategy. The RECORDAF (Registry on
Cardiac Rhythm Disorders Assessing the Control of Atrial
Fibrillation) was established to investigate “real-world”
treatment of patients assigned, on clinical grounds, to a
rate-control or rhythm-control strategy. The RECORDAF is
the first worldwide, 1-year observational, longitudinal study
of the treatment of patients with recently diagnosed parox-
ysmal or persistent AF.
Methods
The primary objectives of the RECORDAF were to pro-
spectively assess therapeutic success and clinical outcomes
with rhythm- and rate-control strategies. Physicians were
randomly selected from an exhaustive global list of office- or
hospital-based (university/nonuniversity, private/clinic) car-
diologists. Consecutive patients age 18 years and older were
considered for enrollment if they presented with AF or a
history of AF (1 year from diagnosis, irrespective of
whether AF was treated and of the rhythm at inclusion)
received a diagnosis based on a standard electrocardiogram
(ECG) or Holter monitoring and were eligible for pharma-
cological treatment of AF by rhythm- or rate-control
agents. Exclusion criteria included permanent AF or a
transient/reversible cause of AF. All patients signed an
informed consent form. Data were collected at baseline
(visit 0), 6  2 months (visit 1: nonmandatory), and 12 
3 months (visit 2).
Management of AF was considered a therapeutic success
if the following conditions were met: 1) for the rhythm-
Abbreviations
and Acronyms
AF  atrial fibrillation
CAD  coronary artery
disease
CI  confidence interval
ECG  electrocardiogram
MI  myocardial infarction
OR  odds ratio
TIA  transient ischemic
attackcontrol strategy, AF was said to be controlled if the patientwas in sinus rhythm on the ECG at the 12-month visit;
2) for the rate-control strategy, the patient had a resting
heart rate of 80 beats/min on the ECG at the 12-month
visit. Therapeutic success also required that no crossover
between strategies had been made and no clinical outcome
had occurred between the baseline and 12-month visits.
Multiple clinical outcomes were measured to evaluate in
detail the impact of cardiovascular risk factors (including the
control of AF). Hence, the occurrence of at least 1 of the
following events was counted between baseline and 12
months: cardiovascular death; stroke, or transient ischemic
attack (TIA) leading to hospitalization; myocardial infarc-
tion (MI); hospitalization for arrhythmic/proarrhythmic
events, hospitalization for complications of ablation proce-
dures, but not the actual procedures; and other cardio-
vascular events (congestive heart failure, unstable angina,
peripheral ischemic events, percutaneous coronary interven-
tion, coronary artery bypass graft, valvular surgery, carotid
angioplasty, carotid endarterectomy, other cardiac or vascu-
lar surgery). Cardiovascular death reported until the end of
the 15th month after baseline was counted as a clinical
outcome in the 12-month analysis.
To estimate a success rate of approximately 50% at 1 year
with 5% precision and 95% confidence intervals (CIs), 384
assessable patients per region/country were needed. With an
expected lost-to-follow-up rate of 25%, approximately
6,100 patients were to be included to provide 4,600 assess-
able patients. Primary endpoints were therapeutic success
and the presence of clinical outcome events. Secondary
endpoints were assessment of AF control, proportion of
patients in sinus rhythm, treatment modalities, and adverse
reactions to AF treatments.
Statistical methods. Descriptive information is summa-
rized as mean SD and the number of nonmissing data for
quantitative data. Categorical data are summarized as num-
ber and percentage of the population with nonmissing data.
Baseline characteristics were compared between groups
using a chi-square test (categorical variables), analysis of
variance, and a Wilcoxon test (continuous variables). Data
collection and statistical analyses were performed by an
external contract research organization, Lincoln Pharma-
ceuticals Ltd. (Gujarat, India).
To identify factors associated with clinical outcomes and
therapeutic success, univariate analyses were performed,
with subgroup comparisons made by chi-square tests; mul-
tivariable stepwise logistic regressions were also performed
on clinical outcomes, therapeutic success, and progression to
permanent AF at 1 year, with a p value of 0.05 required for
entering and retaining the variable in the model. Discrim-
ination between models was assessed using c-statistics, and
calibration was assessed using Hosmer-Lemeshow chi-
square statistics. Odds ratios (ORs) and associated 95% CIs
for therapeutic success, for having a clinical outcome, or for
progression into permanent AF were determined. Multi-
variable analyses were adjusted for country.
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strategy chosen at baseline was calculated; a stepwise logistic
regression was used to estimate the score for each patient,
and covariates were retained in the model if they were
significant at the 0.50 level. Variables used to calculate the
propensity score were age, sex, body mass index, country,
AF classification (new diagnosis/paroxysmal/persistent),
duration of AF (3 months, 3 months), symptoms (at
baseline or during the previous year), family history of AF,
and history of MI, valvular heart disease, diabetes, dyslipi-
demia, carotid stenosis, heart failure (New York Heart
Association functional class), and smoking status. Strata
were created, defined by the quintiles of the propensity
score. The effect of the strategy across strata was tested
using the Mantel-Haenszel pooled estimate. The variables
used in the models to predict outcomes, in addition to those
used in the propensity score calculation, were a history of
coronary artery disease (CAD), arterial hypertension, renal
disease, stroke or TIA, and heart rate; the baseline status of
AF was added for the analysis of progression into perma-
nent AF.
A subset of patients at high risk of stroke and cardiovas-
cular events was selected according to baseline characteris-
tics: paroxysmal/persistent AF and age 75 years and older or
70 years and older with1 risk factor: treated hypertension,
diabetes, previous stroke/TIA, left ventricular ejection frac-
tion 0.40. This population differed from the ATHENA
(A Placebo-Controlled, Double-Blind, Parallel Arm Trial
to Assess the Efficacy of Dronedarone 400 mg bid for the
Prevention of Cardiovascular Hospitalization or Death
Baseline Characteristics in the RECORDAF Patients According to TTable 1 Baseline Characteristics in the RECORDAF Patients A
Variable Rhythm-Control Strategy
Age, yrs 64 12.0 (n  3,076)
Sex
Male 1,755/3,076 (57.1)
Race
Caucasian 2,578/2,865 (90.0)
Black 31/2,865 (1.1)
Asian 167/2,865 (5.8)
Other 89/2,865 (3.1)
Resting heart rate, beats/min 76.6 20.9 (n  3,071)
Atrial fibrillation on baseline ECG 1,172/3,047 (38.5)
First AF diagnosis 180/3,076 (5.9)
Diagnosis in the previous year 2,863/3,076 (93.1)
Paroxysmal AF 1,938/2,863 (67.7)
Persistent AF 925/2,863 (32.3)
Lone AF 650/3,017 (21.5)
Arrhythmia other than AF 425/3,015 (14.1)
Symptomatic AF (at the time of the visit
or during previous year)
2,608/3,075 (84.8)
Valvular heart disease 472/3,047 (15.5)
Stroke 151/3,057 (4.9)
Heart failure 692/3,075 (22.5)
History of diabetes 445/3,074 (14.5)Values are mean  SD or n/N (%).
A  analysis of variance; AF  atrial fibrillation; BMI  body mass index; C  chi-square test; ECG  efrom Any Cause in Patients with Atrial Fibrillation/Atrial
Flutter) trial population in that left atrial dimension was not
a selection criterion, and symptom duration was limited to
12 months.
Analyses were performed with SAS statistical software,
version 9.1 (SAS Institute, Cary, North Carolina).
Results
In total, 5,604 patients were eligible for analysis (Table 1),
recruited from 532 sites in 21 countries across Europe, Amer-
ica, and Asia. The RECORDAF included areas reported to
have a high burden of coronary heart disease (e.g., Eastern
Europe, Russia, and Asia) (5), and differing antithrombotic use
(6–9) . Patient characteristics and AF management at baseline
have been described previously (10).
Overall, patients assigned to a rhythm-control strategy
were younger; more frequently symptomatic; more likely to
have recently diagnosed AF, paroxysmal AF, or a history of
lone AF; and had a lower resting heart rate compared with
patients allocated to a rate-control strategy. A rate-control
strategy was more often selected in patients with a history of
heart failure, valvular heart disease, stroke, or diabetes,
presenting with persistent AF, previous electrocardio-
graphic evidence of AF, and the presence of AF at the
inclusion visit. Most patients had a history of arterial
hypertension (68%), and 42% had a history of dyslipidemia.
AF evolution. At 1 year, 5,171 patients (92.3%) were
assessable, with 81% of patients selected for a rhythm-
control strategy remaining in sinus rhythm (44% at base-
ent Strategying to Treatment Strategy
Rate-Control Strategy Total p Value
67 11.6 (n  2,528) 66 11.9 (N  5,604) 0.001 (A)
0.751 (C)
1,453/2,528 (57.5) 3,208/5,604 (57.2)
0.001 (C)
1,990/2,451 (81.2) 4,568/5,316 (85.9)
57/2,451 (2.3) 88/5,316 (1.7)
352/2,451 (14.4) 519/5,316 (9.8)
52/2,451 (2.1) 141/5,316 (2.7)
0.6 19.1 (n  2,525) 78.4 20.2 (n  5,596) 0.001 (W)
2,007/2,494 (80.5) 3,179/5,541 (57.4) 0.001 (C)
120/2,528 (4.7) 300/5,604 (5.4) 0.050 (C)
2,391/2,528 (94.6) 5,254/5,604 (93.8)
810/2,391 (33.9) 2,748/5,254 (52.3)
1,581/2,391 (66.1) 2,506/5,254 (47.7)
394/2,522 (15.6) 1,044/5,593 (18.7) 0.001 (C)
293/2,480 (11.8) 718/5,495 (13.1) 0.013 (C)
1,911/2,523 (75.7) 4,519/5,598 (80.7) 0.001 (C)
594/2,486 (23.9) 1,066/5,533 (19.3) 0.001 (C)
166/2,515 (6.6) 317/5,572 (5.7) 0.008 (C)
760/2,525 (30.1) 1,452/5,600 (25.9) 0.001 (C)
434/2,526 (17.2) 879/5,600 (15.7) 0.006 (C)reatmccord
8lectrocardiogram; W  Wilcoxon test.
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strategy were in AF (57% at baseline) (Table 2). The
RECORDAF did not enroll permanent AF patients, but
evolution to permanent AF occurred in 1,500 patients
(31%) by visit 2 (rhythm control 13%; rate control 54%).
Male patients made up 57% of those whose AF progressed
to permanent.
Multivariable analysis demonstrated that presenting with
a diagnosis of persistent AF, heart failure (New York Heart
Association functional class I/II), a longer history of AF,
and age older than 75 years predicted AF progression,
whereas entering the study in sinus rhythm and the choice
of rhythm control predicted that the arrhythmia would not
progress (Fig. 1). When the propensity score was applied,
the impact of the treatment strategy was as follows: OR:
0.20, 95% CI: 0.17 to 0.25; p  0.0001.
Strategies, treatment, and adverse events. Overall, 52%
of patients had a change in pharmacological treatment
(rhythm control, 55%; rate control, 47%), 9% had a phar-
macological conversion, and 10% had an electrical cardio-
AF Status at 1 YearTable 2 AF Status at 1 Year
Rhythm-Control S
Sinus rhythm* 2,247/2,791 (
AF 541/2,791 (
Paroxysmal AF 1,883/2,687 (
Persistent AF 447/2,687 (
Permanent AF† 357/2,687 (
Symptoms at the time of the visit‡ 583/2,799 (
Values are n/N (%). *At baseline, 44%were in sinus rhythm, and 57%w
symptomatic at the time of the baseline visit.
AF  atrial fibrillation.
Figure 1 Baseline Factors Predicting Progression to Permanen
Forest plot of multivariable analysis of baseline factors predicting progression to p
c-statistics  0.90, Hosmer-Lemeshow p  0.16. HF  heart failure; NYHA  Neversion. Treatment using antiarrhythmic drug classes and
rate-control agents was similar between baseline and visit 2
(class I antiarrhythmic drugs, 12% at both visits; class III
antiarrhythmic drugs, 29% vs. 26%; heart rate–lowering
calcium-channel blockers, 10% at both visits; cardiac glyco-
sides, 20% at both visits). Two percent of rhythm-control
patients had catheter ablation and 0.3% had surgical therapy
for AF. Two percent of patients underwent a pacemaker
implantation, 5% of patients had a new diagnosis of other
arrhythmia (same in both strategies), but no cases of torsade
de pointes were reported.
In total, 28% of patients had 1 treatment-related
adverse events, mostly general side effects (13%) and mild
electrocardiographic changes (9%) (Table 3).
At baseline, a rhythm-control strategy was selected in
55% of patients and a rate-control strategy in 45%. At 1
year, 78% of patients in each group remained on the same
strategy.
Ninety percent of patients received antithrombotic therapy
at 1 year, although only 52% were treated with a vitamin K
gy Rate-Control Strategy Total
712/2,147 (33.2) 2,959/4,938 (59.9)
1,432/2,146 (66.7) 1,973/4,937 (40.0)
640/2,123 (30.1) 2,523/4,810 (52.5)
340/2,123 (16.0) 787/4,810 (16.4)
1,143/2,123 (53.8) 1,500/4,810 (31.2)
433/2,164 (20.0) 1,016/4,963 (20.5)
F. †No permanent AF was found at baseline. ‡Forty-nine percent were
ent atrial fibrillation (AF) (odds ratio, 95% confidence interval).
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antiplatelet agents; the mean (SD) duration of intake of
vitamin K antagonists during the study was 10.8 (3.5)
months. In 46% of patients, the CHADS2 score was 2 at
year; 64 patients (1.3%) had an increased score compared
ith baseline. Fifty-nine percent of patients with a
HADS2 score 2 (at baseline or 1 year) were treated with
vitamin K antagonist.
ndpoints. Clinical outcome events occurred in 18% of
atients: 17% of patients when the strategy chosen at
aseline was rhythm control and 18% when it was rate
ontrol (Table 4). Cardiovascular death occurred in 1.7% of
atients (rhythm control, 0.9% vs. rate control, 2.8%), MI in
.7% (0.5% vs. 0.9%), stroke/TIA in 2.1% (1.7% vs. 2.8%),
nd all-cause mortality in 3% (1.9% vs. 4.2%). Hospitaliza-
ions for cardiovascular reasons occurred in 16.7% of the
opulation, and rates were similar for both treatment
trategies (rhythm control 16.6%; rate control 16.7%).
Baseline factors significantly increasing the risk of clinical
vents in a univariate analysis were presence of symptoms at
aseline/during the previous year; a history of CAD, MI,
troke/TIA, carotid stenosis, hypertension, heart failure,
yslipidemia, diabetes, valvular heart disease, arrhythmia
ther than AF, or the presence of renal disease; treatment
Adverse Events Occurring During the 1-Year SurTable 3 Adverse Events Occurring During th
Adverse Events Rhythm-Control Strat
Any adverse event 801/2,795 (28.6)
Gastrointestinal 161/2,782 (5.8)
Cardiac side effect 198/2,782 (7.1)
Heart failure 36/2,782 (1.3)
Electrocardiographic change 284/2,776 (10.2)
Sinus bradycardia 149/2,776 (5.4)
Organ toxicity 130/2,782 (4.7)
General side effect 343/2,791 (12.3)
Bleeding related to OAC 93/2,785 (3.3)
Values are n/N (%).
OAC  oral anticoagulant.
Clinical Outcomes at 1 YearTable 4 Clinical Outcomes at 1 Year
Clinical Events
Any clinical event
CV death
Stroke or TIA
Myocardial infarction
Hospitalization or prolongation of hospitalization for arrhythmia or proarrhythmia
Hospitalization or prolongation of hospitalization for other
CV events or interventions
Congestive heart failure
Unstable angina
Other
Hospitalization or prolongation of hospitalization for major complications
of ablative procedure
Hospitalization for CV event: yesValues are n/N (%).
CV  cardiovascular; TIA  transient ischemic attack.ith antithrombotic drugs; and a CHADS2 score 2.
Baseline factors decreasing the risk of clinical events were
lone AF and the absence of symptoms at baseline/during the
previous year.
The multivariable model (Fig. 2) demonstrated that
adverse clinical outcomes were predominantly influenced by
history of heart failure (e.g., New York Heart Association
functional class III to IV, OR: 2.03, 95% CI: 1.38 to 2.99)
and higher heart rate (OR: 1.009 per 1-beat increase, 95%
CI: 1.004 to 1.01), whereas a longer (3 months) duration
of AF (OR: 0.82, 95% CI: 0.69 to 0.97) led to improved
outcomes. The rhythm-control strategy did not affect clin-
ical outcomes.
Control of AF, as defined here, was obtained in 78% of
patients, whereas 22% had a strategy change between
baseline and 1 year. The composite endpoint of therapeutic
success was met in 54% of patients (rhythm control 60% vs.
rate control 47%) (Table 5). Post-hoc analyses testing
different cutoff values for resting heart rates were also
performed: rates 85 beats/min demonstrated a better
therapeutic success for the rhythm-control group compared
with the rate-control group (60% vs. 52%, respectively, p 
0.0001); however, rates 90 beats/min neutralized thera-
peutic success (60% vs. 58%, p  0.0652), as did rates 95
ear Survey
Rate-Control Strategy Total
598/2,180 (27.4) 1,399/4,975 (28.1)
126/2,164 (5.8) 287/4,946 (5.8)
198/2,162 (9.2) 396/4,944 (8.0)
67/2,162 (3.1) 103/4,944 (2.1)
165/2,153 (7.6) 449/4,929 (9.1)
60/2,153 (2.8) 209/4,929 (4.2)
47/2,162 (2.2) 177/4,944 (3.6)
310/2,165 (14.3) 653/4,956 (13.2)
89/2,165 (4.1) 182/4,950 (3.7)
hm-Control Strategy Rate-Control Strategy Total p Value
83/2,809 (17.2) 405/2,225 (18.2) 888/5,017 (17.7) 0.352
24/2,804 (0.9) 61/2,213 (2.8) 85/5,034 (1.7) 0.001
46/2,784 (1.7) 60/2,179 (2.8) 106/4,963 (2.1) 0.008
14/2,785 (0.5) 20/2,175 (0.9) 34/4,960 (0.7) 0.078
14/2,790 (11.3) 159/2,179 (7.3) 473/4,969 (9.5) 0.001
90/2,791 (6.8) 204/2,182 (9.3) 394/4,973 (7.9) 0.001
67/2,791 (2.4) 104/2,182 (4.8) 171/4,973 (3.4) 0.001
35/2,791 (1.3) 33/2,182 (1.5) 68/4,973 (1.4) 0.436
04/2,791 (3.7) 103/2,182 (4.7) 207/4,973 (4.2) 0.082
15/2,786 (0.5) 14/2,171 (0.6) 29/4,957 (0.6) 0.626
65/2,793 (16.6) 366/2,195 (16.7) 831/4,988 (16.7) 0.891veye 1-Y
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(60% vs. 62%, p  0.2842).
Baseline factors significantly increasing therapeutic suc-
cess in the univariate analysis were age younger than 65
years, paroxysmal AF, lone AF, treatment with class I
antiarrhythmic drug (vs. no class I), treatment with anti-
thrombotic drugs, and choice of a rhythm-control strategy.
Factors significantly decreasing success were persistent AF;
a history of CAD, MI, stroke/TIA, carotid stenosis, heart
failure, diabetes, or valvular heart disease; a CHADS2 score
2; and choice of a rate-control strategy.
In a multivariable analysis, prognostic factors significantly
ncreasing the chance of therapeutic success at 1 year,
djusted for baseline differences (Fig. 3) were rhythm-
ontrol strategy (OR: 1.67, 95% CI: 1.45 to 1.91; p 
.0001), absence of CAD, absence of heart failure, age 75
ears and younger, and no previous stroke/TIA (c-statistics 
.62, Hosmer-Lemeshow p  0.22). When the propensity
core quintile was used, a higher therapeutic success rate was
Figure 2 Baseline Factors Predicting Clinical Outcomes
Forest plot of multivariable analysis of baseline factors predicting clinical outcome
Hosmer-Lemeshow p  0.28. Abbreviations as in Figure 1.
Therapeutic Success at 1 YearTable 5 Therapeutic Success at 1 Year
Rh
Therapeutic success 1,69
Control of atrial fibrillation 2,24
Change in strategy between baseline and 1 year 61
No clinical outcome 2,32Values are n/N (%).till predicted for the rhythm-control strategy (OR: 1.34,
5% CI: 1.15 to 1.55; p  0.0002).
In an analysis that included the composite CHADS2 score
rather than its constituent parameters, the statistical fit was less
good (c-statistics  0.62, Hosmer-Lemeshow p  0.01).
However, a CHADS2 score 2 predicted a lower probability
f therapeutic success (OR: 0.71, 95% CI: 0.62 to 0.81; p 
.0001), and treatment strategy remained the most significant
actor (OR: 1.71, 95% CI: 1.49 to 1.95; p  0001).
ubgroup analysis. Among the 5,171 patients assessable at
year, 1,951 patients (38%) were at high risk of stroke and
ajor cardiovascular events (i.e., they fulfilled the
THENA trial [11] inclusion criteria [except time from
F diagnosis and left atrial dimension criteria]). Clinical
utcomes occurred in 20% of patients in this subgroup: 21%
hen the baseline strategy was rhythm control, 19% when it
as rate control. Cardiovascular death occurred in 2.2% of
atients (1.4% vs. 3%). AF control was achieved in 76% of
atients, whereas 24% underwent a strategy change between
s ratio, 95% confidence interval). c-statistics  0.67,
Control Rate Control Total
14 (60.1) 1,026/2,208 (46.5) 2,717/5,022 (54.1)
91 (80.5) 1,561/2,122 (73.6) 3,808/4,913 (77.5)
96 (22.1) 497/2,182 (22.8) 1,115/4,978 (22.4)
09 (82.8) 1,820/2,225 (81.8) 4,146/5,034 (82.4)s (oddythm
1/2,8
7/2,7
8/2,7
6/2,8
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registry population. Therapeutic success was achieved in
51% of patients (rhythm control, 54%; rate control, 48%).
Discussion
RECORDAF. A large-scale longitudinal registry of AF
patients treated according to clinical principles and practice
offers an opportunity to seek information complementing
that derived from randomized clinical trials. More than
5,000 patients were recruited to RECORDAF and followed
for 1 year to statistically evaluate clinical outcomes and
therapeutic success associated with rate-control and
rhythm-control strategies in real life.
Clinical outcomes. Although clinical outcomes were doc-
umented in 18% of patients, there was no difference
between strategies. Predictably, baseline characteristics fore-
casting adverse outcomes in multivariable analysis were
renal disease, CAD, heart failure, previous stroke, and age.
Furthermore, symptoms (recorded at baseline/during the
previous year) predicted an adverse outcome independent of
associated cardiovascular disease. It was hypothesized that
symptoms may be more prominent in those with faster heart
rates, but the statistical model demonstrated that heart rate
had only a minor effect and that symptom effect was
independent. However, it may be that symptoms drive
hospitalizations or are a surrogate for unmeasured variables
relating to greater illness severity.
A short duration of AF (3 months) was associated with
worse outcomes, consistent with the findings from the
AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) clinical study and the EUROHEART
AF survey that new-onset AF has an adverse prognosis (11).
Figure 3 Baseline Factors Predicting Therapeutic Success
Forest plot of multivariable analysis of baseline factors predicting therapeutic succ
Hosmer-Lemeshow p  0.22. Abbreviations as in Figures 1 and 2.Presumably, this is related to the adverse effect of the comor-bidities that caused the AF to be discovered or precipitated the
arrhythmia.
Although clinical outcome rates were not significantly
different between treatment strategies, more serious events,
including hospitalization for heart failure, occurred in pa-
tients receiving a rate-control strategy because these patients
had a more severe risk profile than patients in the rhythm-
control group. However, more hospitalizations for arrhyth-
mias/proarrhythmias were observed in patients treated with
a rhythm-control strategy.
Rate versus rhythm strategy. Despite considerable clinical
trial data that led many physicians to conclude that AF is as
well, if not better, managed with a rate-control strategy than
with a rhythm-control strategy, the RECORDAF found
that physicians generally prefer rhythm-control strategies.
Cited reasons include the limitations of randomized trials,
particularly the restricted nature of patient enrollment, and
the clinical applicability of conclusions drawn from studies
in which strategies are persistently applied despite their
failure to control AF. Results from the largest of the
rate-versus-rhythm trials (AFFIRM) indicate that patients
who are in sinus rhythm, regardless of the strategy assign-
ment, do better with regard to specific clinical outcomes,
such as risk of death, than those who have AF (12). In this
same trial, nearly 45% of screened candidates were not
enrolled (1).
Subgroup analysis. The secondary analysis of a subset of
patients with characteristics similar to those recruited in the
ATHENA trial (13) did not reveal any substantial differ-
ences. Total clinical outcomes, cardiovascular death, and
hospitalization for cardiovascular events were slightly, but
not significantly, in favor of rhythm control. This popula-
tion is of particular interest in view of the important
dds ratio, 95% confidence interval). c-statistics  0.62,ess (odecrease in hospitalizations and cardiovascular mortality in
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Differences in Clinical Outcomes in the RECORDAF July 26, 2011:493–501such patients when treated with dronedarone (13), an
antiarrhythmic drug recently approved in North America
and the European Union for the management of AF with
associated cardiovascular risk factors.
Therapeutic success. In the RECORDAF, therapeutic
uccess at 1 year was achieved in 54% of patients (rhythm
ontrol, 60%; rate control, 47%), but approximately one-half
f patients had changed their pharmacological AF treat-
ent since baseline. Although the use of a single ECG as a
easure of therapeutic success is quite limited, especially for
atients with paroxysmal AF, the rhythm-control success
ate (81%) established in the RECORDAF was almost
dentical to the overall success at maintaining sinus rhythm
chieved in the first antiarrhythmic drug substudy of the
FFIRM study (14).
Moreover, the statistically significant higher therapeutic
uccess associated with rhythm control in the multivariable
nalysis was largely due to the failure of therapy in the
ate-control group to reduce heart rate to 80 beats/min.
his heart rate was chosen in line with that in the AFFIRM
tudy (1) and subsequent AF guidelines (15). Post hoc
nalyses using higher cutoff values for heart rate gave neutral
esults with regard to overall therapeutic success.
dequate rate control: heart rate definition. The choice
f a specific resting heart rate to define adequate rate control
emains arbitrary. The American College of Cardiology/
merican Heart Association/European Society of Cardiol-
gy guidelines define adequate resting heart rate control as
0 to 80 beats/min. Although 80 beats/min was selected
y the AFFIRM study investigators (1), a definition of
100 beats/min was chosen in the RACE (RAte Control
fficacy in permanent AF) trial (2). A subsequent compar-
son between outcomes in these trials failed to show any
ifference (16). Similarly, in the AFFIRM study, the clinical
utlook was not improved for those meeting rate-control
riteria compared with those who did not (17). However,
ata from the RACE II trial comparing strict and lenient
ate control have now been published (18). Although the
rial did not show any advantage from strict compared with
enient rate control, only relatively well patients were en-
olled, the trial was small, and a large composite primary
ndpoint was used. In light of the important disadvanta-
eous effect of faster rates during sinus rhythm (19–21), it is
uite possible that a trial of sufficient size and duration in
ick patients with AF and with a greater heart rate difference
etween lenient and strict rate-control arms would show a
imilar detrimental effect of higher heart rates in AF. Thus,
0 beats/min was chosen as the protocol definition of
dequate rate control for the RECORDAF.
rogression to permanent AF. The 12-month follow-up
n the RECORDAF showed a remarkable progression to
ermanent AF in patients treated with a rate-control
trategy (none at baseline vs. 54% at 1 year). Because this
lassification was based on the investigators’ clinical judg-
ent, it may be that the observation is partly semantic, thehoice of rate control implying that AF is permanent. rlternatively, it may signal an important shift in attitude.
hen choosing rate control, physicians accept that AF will
nevitably become permanent; conversely, only 13% of
atients receiving rhythm-control therapy were subse-
uently designated as having permanent AF. Furthermore,
here was a substantial difference between those who were
ocumented to be in AF at visit 2 (rhythm control, 19% vs.
ate control, 67%) compared with baseline (39% vs. 81%).
hese results may suggest an increased likelihood of the
evelopment of permanent AF if a rate-control strategy is
hosen. Consequently, for any patient for whom a rhythm
olution might later be chosen, there exists a clinical
rgument to persist with a rhythm-control strategy until
efinitive rhythm control can be offered.
It is generally believed that rate control is more simply
nd easily achieved than rhythm control (22). However, the
esults of the RECORDAF do not support this: a change of
trategy, from rate control to rhythm control or vice versa,
as similar in both groups. In addition to the failure of rate
ontrol to reach acceptable resting heart rates, 47% of
atients required therapy adjustment (addition or exchange
f rate-control medications) compared with 55% in the
hythm-control arm. Symptom resolution was identical in
oth groups, and similar frequencies of treatment-related
dverse events were reported with both strategies.
tudy limitations. A registry-based study has clear intrin-
ic limitations. Importantly, in this study, the rate- and
hythm-control groups were very different because the
atients were not randomized to treatment assignment.
hose who received rate-control therapy had worse under-
ying heart disease (e.g., only 16% of the rate-control group
ad lone AF compared with 19% of the rhythm-control
roup [p  0.001]), and any valid comparison between the
roups therefore relies on multivariable statistical analysis.
he analyses in this study incorporated many variables that
ould be derived from history taking, but the patients were
ot extensively or consistently investigated with noninvasive
r invasive techniques. The models successfully accounted
or 62% (therapeutic success) and 67% (clinical outcomes) of
he risk attributable to factors other than AF.
The registry included multiple countries, giving a global
erspective, but including regional differences in clinical
trategy, patient baseline variables, and recruitment setting
outpatient vs. inpatient). Individual country analysis may
herefore be of value but, due to sample size, may not be
owered to report statistical differences.
Success with the rhythm-control strategy was defined as
inus rhythm present at the 12-month visit. An ECG at a
ingle point in time might represent an inadequate indication
f the frequency of AF, and it is possible that patients with
requent AF who are in AF one-half of the time could be
lassified as having successful rhythm control in the
ECORDAF. In this real-life observational registry, close
onitoring of AF recurrences could not be achieved.
Success of rate control was defined per protocol as aesting heart rate 80 beats/min at the 12-month visit, but
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evaluation during activity or exertion is lacking.
The criteria for AF control were necessarily different for
each strategy and, because they are arbitrary, the outcome of
therapeutic success incorporating AF control should be
interpreted with caution. Nevertheless, in clinical practice,
AF control and therapeutic success are judged on a patient
basis using similar pragmatic observations by which to infer
the likely intermediate and longer-term outcome.
Therapeutic success also required that no change in
therapeutic strategy (rate control vs. rhythm control) and
that no clinical outcome as mentioned in the protocol had
occurred. Therapeutic strategy and changes were deter-
mined by the treating physician, and it is likely that
treatment varied by physician, region, or country.
Longitudinal registries are difficult to complete because
patients and physicians may lose their enthusiasm for the
study, but in this case, a majority of patients completed the
1-year follow-up (92%).
Conclusions
The RECORDAF, despite limitations inherent in real-life
observational studies, has shown that within 12 months,
clinical outcomes are not influenced by the choice of rhythm
control versus rate control, but are mainly driven by hospi-
talizations due to arrhythmia/proarrhythmia and other car-
diovascular causes. Nevertheless, AF is better controlled in
clinical terms with a rhythm-control strategy, and the
likelihood of progression to permanent AF is less with
rhythm-control than with rate-control therapy. However,
major cardiovascular outcomes are more dependent on
comorbidity than the choice of cardiac rhythm manage-
ment. The RECORDAF confirms and complements
results reported in previous rate-control versus rhythm-
control randomized, controlled trials.
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